Drugs / Enteric Coated Mycophenolate Sodium (EC-MPS)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00413920 | Apr 2007 → Mar 2009 | — | Novartis | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT01843348 Comparator | Dec 2012 → Mar 2016 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00634920 Background | Mar 2008 → May 2013 | impaired renal function disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00332839 Background | Nov 2005 → Mar 2013 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enteric Coated Mycophenolate Sodium (EC-MPS) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01843348 ↗ |
| Known as | EC-MPS | “Drug: Enteric-coated mycophenolate sodium (EC-MPS)” NCT00413920 ↗ |
| Route | Oral | “Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months.” NCT00413920 ↗ |